Marinova Pty Ltd, a specialist in fucoidan research and ingredients, has announced that it will investigate the potential for its high purity seaweed extracts in supporting measures of prostate health.
 
“Benign prostatic hyperplasia (BPH), or prostate enlargement, is a significant health issue for men across the globe,” said Corinna Dwan, PhD, scientific affairs director at Marinova. “The condition becomes increasingly prevalent with age, and while it is typically non-life threatening, it can cause bothersome symptoms including difficulty passing urine and an increase in the frequency of urination. BPH may also lead to bladder, urinary tract, or kidney problems.”
 
Marinova noted that a recent published animal study found that a 28-day treatment of fucoidan was associated with significant improvements of testosterone-induced BPH symptoms in rats. “Significant reductions in prostate weight, prostate index, testosterone, dihydrotestosterone, and prostate-specific antigen levels were observed in rats supplemented with fucoidan, compared to the BPH control group. Additionally, the anti-inflammatory and pro-apoptotic potential of fucoidan observed in this study may help to explain how fucoidan acts to ameliorate the effects of BPH,” said Dwan.  
 
“Marinova is continuing its investigation into the potential of fucoidan to support prostate health and looks forward to sharing further details in due course,” said Dwan. “As the search for natural, non-toxic and bioactive compounds to support men’s health intensifies, further results will inevitably be of interest to the global research community.”